Pliant rises after FDA grants fast-track tag to experimental cancer drug

Pliant Therapeutics

18/08/2026 13:59

** Shares of biotech firm Pliant Therapeutics PLRX.O rise 7% to $1.17 premarket
** Co says FDA grants Fast Track designation to experimental cancer drug PLN-101095 in combination with Merck's Keytruda
** Fast Track status is for patients with advanced solid tumors that no longer respond to immune checkpoint inhibitors, a type of cancer treatment that helps the immune system attack tumors
** PLN-101095 is being tested in an early-stage study in patients with lung cancer, kidney cancer and tumors with high mutation levels
** Fast-track status is meant to speed development and review of treatments for serious diseases with unmet medical need
** Pliant expects data from the trial in 2027
** As of last close, stock down ~10% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))